Who
Deborah Ascheim
Director
Company insider
Files Form 4 as: Director, Longeveron; Chief Medical Officer, Capricor Therapeutics.
In numbers
- Trades disclosed
- 6
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 18 Sep 2015
- Last trade
- 19 Aug 2026
- Last filed
- 21 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Aug 2026filed 21 Aug 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 24 Jul 2018filed 25 Jul 2018 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jan 2018filed 4 Jan 2018 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,122 at $0.00 | filing |
| 3 Jan 2017filed 4 Jan 2017 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 18 Sep 2015filed 21 Sep 2015 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.